Patrick Grohar
Faculty Member
Last active: 3/27/2014

  1. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, Helman LJ (2014) Clin Cancer Res 20(5): 1190-203
    › Primary publication · 24277455 (PubMed) · PMC5510643 (PubMed Central)
  2. Prospects and challenges for the development of new therapies for Ewing sarcoma. Grohar PJ, Helman LJ (2013) Pharmacol Ther 137(2): 216-24
    › Primary publication · 23085431 (PubMed) · PMC7243921 (PubMed Central)
  3. Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, Khan J, Hewitt SM, Khanna C, Staudt LM, Helman LJ (2013) Oncogene 32(47): 5429-38
    › Primary publication · 23318429 (PubMed) · PMC3898328 (PubMed Central)
  4. A Decade in Banking Ewing Sarcoma: A Report from the Children's Oncology Group. Borinstein SC, Beeler N, Block JJ, Gorlick R, Grohar P, Jedlicka P, Krailo M, Morris C, Phillips S, Siegal GP, Lawlor ER, Lessnick SL, COG Ewing Sarcoma Biology Committee (2013) Front Oncol : 57
    › Primary publication · 23519678 (PubMed) · PMC3602933 (PubMed Central)
  5. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, Currier DG, Davis S, Khanna C, Khan J, McMahon JB, Helman LJ (2011) J Natl Cancer Inst 103(12): 962-78
    › Primary publication · 21653923 (PubMed) · PMC3119649 (PubMed Central)
  6. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J, Helman LJ (2011) Neoplasia 13(2): 145-53
    › Primary publication · 21403840 (PubMed) · PMC3033593 (PubMed Central)
  7. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ (2007) Oncogene 26(13): 1932-40
    › Primary publication · 17001314 (PubMed)
  8. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar PJ, Ravindranath Y, Matherly LH, Taub JW (2004) Cancer Res 64(2): 728-35
    › Primary publication · 14744791 (PubMed)
  9. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity. Schroeder MC, Hamby JM, Connolly CJ, Grohar PJ, Winters RT, Barvian MR, Moore CW, Boushelle SL, Crean SM, Kraker AJ, Driscoll DL, Vincent PW, Elliott WL, Lu GH, Batley BL, Dahring TK, Major TC, Panek RL, Doherty AM, Showalter HD (2001) J Med Chem 44(12): 1915-26
    › Primary publication · 11384237 (PubMed)
  10. Unique structural and stabilizing roles for the individual pseudouridine residues in the 1920 region of Escherichia coli 23S rRNA. Meroueh M, Grohar PJ, Qiu J, SantaLucia J, Scaringe SA, Chow CS (2000) Nucleic Acids Res 28(10): 2075-83
    › Primary publication · 10773075 (PubMed) · PMC105375 (PubMed Central)